Aurinia Pharmaceuticals Inc
NASDAQ:AUPH 3:59:53 PM EDT
Other Pre-Announcement
Aurinia Reports First Quarter 2022 Financial And Operational Results
Published: 05/10/2022 10:15 GMT
Aurinia Pharmaceuticals Inc (AUPH) - Aurinia Reports First Quarter 2022 Financial and Operational Results.
Q1 Loss per Share $0.27.
Q1 Revenue $21.6 Million.
Maintains Net Revenue Guidance Range of $115-$135 Million From Sales of Lupkynis for 2022.
Aurinia- Review of Ema Marketing Authorization Application Remains on Track With European Commission Approval Expected in Second Half of 2022.
Q1 Earnings per Share View $-0.27, Revenue View $19.8 Million -- Refinitiv Ibes Data (analyst estimates).
Q1 Loss per Share $0.27.
Q1 Revenue $21.6 Million.
Maintains Net Revenue Guidance Range of $115-$135 Million From Sales of Lupkynis for 2022.
Aurinia- Review of Ema Marketing Authorization Application Remains on Track With European Commission Approval Expected in Second Half of 2022.
Q1 Earnings per Share View $-0.27, Revenue View $19.8 Million -- Refinitiv Ibes Data (analyst estimates).